CDXC:NSD-ChromaDex Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.64

Change

0.00 (0.00)%

Market Cap

USD 0.45B

Volume

0.21M

Avg Analyst Target

USD 11.50 (+73.19%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+6.68 (+1.54%)

USD175.20B 51.28 41.56
BNTX BioNTech SE

-2.09 (-0.61%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

+0.11 (+0.02%)

USD69.19B 11.68 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.53 (-0.82%)

USD48.20B 24.50 16.63
BGNE BeiGene Ltd

-0.33 (-0.08%)

USD41.72B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+4.15 (+2.51%)

USD30.02B 51.49 39.11
GMAB Genmab A/S

-0.22 (-0.50%)

USD28.07B 71.33 8.17
RPRX Royalty Pharma plc

-0.34 (-0.93%)

USD22.24B 29.66 12.50
ALNY Alnylam Pharmaceuticals Inc

-1.94 (-1.05%)

USD21.89B N/A N/A

ETFs Containing CDXC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.33% 81% B- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.33% 80% B- 81% B-
Trailing 12 Months  
Capital Gain 62.35% 77% C+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.35% 77% C+ 68% D+
Trailing 5 Years  
Capital Gain 121.33% 76% C 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 121.33% 76% C 73% C
Average Annual (5 Year Horizon)  
Capital Gain 33.56% 65% D 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.56% 65% D 76% C
Risk Return Profile  
Volatility (Standard Deviation) 58.86% 53% F 30% F
Risk Adjusted Return 57.02% 83% B 74% C
Market Capitalization 0.45B 56% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.52 16% F 14% F
Price / Cash Flow Ratio -42.72 88% B+ 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -73.00% 39% F 23% F
Return on Invested Capital -107.70% 17% F 7% F
Return on Assets -28.28% 44% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 13.69 10% F 6% F
Short Percent 8.92% 28% F 20% F
Beta 1.64 34% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector